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Fc = crystallizable fragment [of antibody]; FcγR = Fc IgG receptor; IL = interleukin; SLE = systemic lupus erythematosus; TNF = tumour necrosis
factor.
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Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disease characterised by a striking preponderance in
females, multisystem involvement, and autoantibodies
directed primarily against nuclear antigens. Pathogenic
mechanisms have been partly elucidated and defects in
immune complex clearance, B-cell tolerance, and T-cell
function have all been described. Little, however, is known
about predisposing factors and mechanisms leading to
disease induction. Through a variety of study designs, a
strong genetic predisposition has been shown. For
example, studies of affected probands estimate the sibling
recurrence risk (λs) to be approximately 20. Twin studies
have demonstrated concordance rates among mono-
zygotic twins of 24–65%, compared with 2–9% in
dizygotic twins [1]. SLE is a complex, polygenic trait with
contributions from MHC and non-MHC genes, and up to
100 genes may be involved in disease susceptibility [1].
The study of SLE genetics is at an exciting and rapidly
advancing stage. This review aims to update our current
understanding of this area.
Mouse models of systemic lupus
erythematosus
Genetic analyses in the mouse have provided some impor-
tant insights into the pathogenic processes mediating
disease in experimental models of SLE. Linkage analysis and
congenic dissection have provided insights into the genetic
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Systemic lupus erythematosus is the prototype multisystem autoimmune disease. A strong genetic
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basis for susceptibility in the classic lupus-prone mouse
strains. These studies have delineated specific genetic path-
ways that are critical to the development of severe lupus
nephritis and have identified allele-specific, suppressive
modifiers capable of dramatically influencing disease pro-
gression. The ‘synthesis’ of mouse models of systemic
autoimmunity via the production of targeted gene disruptions
has also helped identify specific genes and gene combina-
tions capable of causing and modifying disease.
The chromosomal locations of genes mediating suscepti-
bility to lupus nephritis or systemic autoimmunity in the
NZB/W, MRL, and BXSB mouse models have been deter-
mined through genome scans [2–5]. These studies show
that lupus susceptibility is inherited in a complex fashion
involving both genetic interactions and additive effects of
individual genes. In all, 31 different gene designations
have been defined thus far, distributed among 21
nonoverlapping 20-cM genome intervals (Table 1). Other
investigators have mapped loci affecting a variety of com-
ponent phenotypes associated with systemic autoimmu-
nity [6]. The genomic segments on murine chromosomes
1, 4, and 7 are associated with disease susceptibility in
multiple strain combinations, suggesting that these inter-
vals contain genes or gene clusters that strongly influence
autoimmunity. The Sle1, Sle2, and Sle3 loci have been
individually identified as the major SLE susceptibility loci in
NZM2410 mice [2] and their immunophenotypes have
been characterised. Sle1 mediates loss of tolerance to
nuclear antigens, Sle2 lowers the activation threshold of B
cells, and Sle3 mediates dysregulation of CD4+ T cells
[2]. The combination of Sle1 with any one of Sle2, Sle3,
or Yaa (autoimmune accelerating gene) on the B6 genetic
background results in the development of systemic
autoimmunity with variably penetrant glomerulonephritis
culminating in renal failure and death. In contrast, two-loci
combinations of any of Sle2, Sle3, or Yaa did not mediate
fatal disease. These results identify Sle1 as a strategic
locus in SLE pathogenesis [7]. The NZW genome also
has four epistatic modifiers, SLE suppressors
(Sles1–Sles4), which suppress autoimmunity. The most
potent,  Sles1, switches off the Sle1 immunophenotype
and can suppress the entire autoimmune pathological
process [8]. Recent fine-mapping analysis of the Sle1
locus has identified a cluster of functionally related loci
(Sle1a–d). These loci share a common pathway leading to
loss of tolerance to chromatin but differ by various other
serological and cellular phenotypes [9]. This potent sus-
ceptibility locus is syntenic with the 1q23–42 segment of
the human chromosome.
Other models of intense interest are those supporting an
apoptosis-related autoantigen clearance defect, for
example C1q knockout, DNase1-deficient, and serum-
amyloid-P-deficient mice. These models have shown
several important pathogenic abnormalities, including
reduced macrophage clearance of apoptotic cells and
increased concentrations of apoptotic bodies, in tissue
samples associated with development of glomerulo-
nephritis [10–13].
Human linkage studies in systemic lupus
erythematosus
The traditional approach for locating a disease gene in
humans is linkage analysis. Results from mouse models of
SLE presented the first evidence for genetic linkage to an
area of chromosome 1 in the mouse that is syntenic to
human chromosome 1q23–42. In 1997, Tsao et al [14]
published linkage evidence on the long arm of chromosome
1q41–42, using 43 families with 52 affected sibling pairs of
mixed origin. Several additional linkage studies have been
performed using sib-pairs and extended family pedigrees
[15–19]. The parameters and test populations for each
study as well as the genomic intervals detected in at least
two mapping studies are summarised in Tables 2 and 3.
As Table 2 shows, there are many sources of variation
between these studies, including ethnic mix, sample size,
specific markers used, and analytic models used. Another
source of variation may relate to clinical phenotypes of the
affected individuals. Localisation of genes with modest
effects by linkage analysis is difficult and such variations
may further limit the power of such studies. Despite these
important limitations, there is some agreement as regards
regions providing evidence of linkage. Several areas on
Table 1
Positions of the named susceptibility loci from murine genome
studies involving NZB, NZW, NZM2410, BXSB, and MRL/lpr
mice (Wakeland et al, 1999) [2].
Chromosome 
location Susceptibility loci
1 Bxs1, Bxs2, Sbw1, Gld, Sle1, Nba2, Lbw7, Bxs3
3 Sles3*
4 Sle2, Sbw2, Lbm1, nba1, Lbw2, Lmb1, Sles2*
5  Sle6, Lmb2, Lbw3
6 Lbw4
7 Lrdm1, Sle5, Sle3, Lbw5, Lmb3, Nba3
9 Sles4*
10 Lmb4
11 Lbw8
12 Lrdm2
17 H2d/z, Sle4, Sles1*
18 Lbw6
19 Fas
* Suppressive modifiers, responsible for the suppression of fatal
disease in the NZW genome.c
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chromosome 1 have been detected (1p36, 1q21–23 and
1q41–42) [15–19] that contain genes of immunological
importance, some of which may have direct relevance to
pathogenic processes in SLE (Table 4). The importance of
using well-defined populations is emphasised by recent
studies of Nordic multi-case families in which a suscepti-
bility locus at chromosome 2q37 (SLEB2) has been
reported [19]. A study of single-case Swedish families
confirmed association with further markers in this region
but, in contrast, there was no linkage to this area in 13
Mexican families [20].
Study of individual genes in systemic lupus
erythematosus
Many individual genes have been studied in SLE and a
comprehensive analysis of these is beyond the scope of
this review. Recent studies do, however, illustrate impor-
tant points that are likely to apply to other genes in SLE.
Poly(ADP-ribose) polymerase
Poly(ADP-ribose) polymerase (‘PARP’) is involved in DNA
repair and apoptosis, both of which may be of relevance in
SLE pathogenesis. The gene for this protein is also within
the area of linkage for SLE (1q41–42). Using a multiallelic
approach using a transmission disequilibrium test, Tsao et
al [21] found a significant association of an 85-bp allele of
the gene for poly(ADP-ribose) polymerase in affected
white patients with SLE. In contrast, Criswell et al [22]
studied three separate cohorts of SLE patients and failed
to confirm this association. Differences in statistical mod-
elling may account for this difference and the original
finding may be a false-positive result.
Mannose-binding protein
This protein has structural and functional similarities to
C1q. Several polymorphisms of the protein have been
described in association with SLE in different populations
[23–24]. Recent evidence also suggests that polymor-
phisms of mannose-binding protein may increase suscep-
tibility to infection in SLE [25].
IL-6
IL-6 is a pro-inflammatory cytokine that has a role in B-cell
maturation and IgG production. High IL-6 production is
associated with a G→C polymorphism at –174 in the pro-
moter region. In a study of 211 German patients with SLE,
Schotte et al [26] found no higher prevalence of the G
allele than in the background population. This allele was,
however, associated with discoid cutaneous lesions and
anti-histone antibodies.
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Table 2
Summary of human linkage studies in systemic lupus erythematosus
Moser et al  Gaffney et al  Gaffney et al  Shai et al  Lindqvist et al 
Study parameter (1998) [15] (1998) [16] (2000) [17] (1999) [18] (2000) [19]
Number of families 94 105 82 80 19
Type of study Extended Sib-pair Sib-pair Extended Extended
pedigrees pedigrees pedigrees
Number of affected individuals 220 220 179 188 44
Number of unaffected individuals 313 155 101 246 52
Number of ethnic groups 2 5 4 2 1
Ethnicity of families studied
White 0 84 64 37 19
Mexican American 0 0 0 43 0
African American 31 6 12 0 0
Hispanic 0 8 5 0 0
European American 55 0 0 0 0
Asian 0 3 0 0 0
Mixed heritage 0 4 1 0 0
Number of loci analysed 312 341 366 350 336
Basis of linkage LOD ≥1.5 LOD  ≥1.0 LOD ≥1.0 NPLZ >1.5 LOD ≥1.0
Statistical methods Model-based,  Nonparametric Nonparametric Nonparametric Model-based
then nonparametric
Information taken from from references [15–19]. LOD = logarithm of the odds; NPLZ = nonparametric linkage Zall statistic.IL-10
IL-10 is a Th2 cytokine that downregulates antigen pre-
sentation and immune complex clearance. IL-10 is
increased in SLE patients and their family members.
Lazarus et al [27] found the IL-10-1082G, IL-10-819C,
and IL-10–592C haplotype was associated with Ro
autoantibodies and renal involvement in white patients
with SLE. In Chinese patients, a different haplotype was
associated with renal disease but not Ro autoantibodies
[28]. These studies found no association with disease
susceptibility. In contrast, Gibson et al [29] found single
nucleotide polymorphisms in the IL-10 promoter region
significantly associated with SLE susceptibility in African
Americans.
Tumour necrosis factor-α α
The tumor necrosis factor (TNF)-α gene lies within the
MHC region on chromosome 6p. The HLA B8, DR3
haplotype has been associated with SLE in whites and
confers a two- to threefold increased risk of SLE [1].
The TNF-α –308A polymorphism is located within the
promoter region of the gene and is associated with
increased production of TNF-α. This polymorphism is in
strong linkage disequilibrium with the HLA B8, DR3
haplotype, but it also has an independent effect in SLE
[1,30]. In addition, Werth et al [31] have demonstrated
an enhanced susceptibility to photosensitive cutaneous
lesions in SLE patients with this polymorphism.
However the TNF-α –308A polymorphism is also in
linkage disequilibrium with other polymorphisms across
the TNF-α locus, and the functional association remains
to be established.
Fc receptors
These receptors play a role in handling of immune com-
plexes as well as in clearance of apoptotic cells. The Fc
IgG receptor FcγRII and FcγRIII genes are both located at
1q23–24, and several polymorphisms have been
described that affect the ability of receptors to bind. In a
prospective study of Hispanic patients with SLE, Zuniga et
al [32] observed that the low-affinity FcγR alleles (RIIa-
R131 and RIIIa-F176) were inherited independently and
were present at higher frequency in patients with SLE,
especially as a haplotype. In SLE patients with nephritis,
there was also a predominance of low-affinity alleles. Hatta
et al [33], studying a Japanese population, also found an
association between FcγRIIIB-NA2/NA2 genotype and
development of SLE with an increased prevalence of
nephritis. Selgiman et al [34] also recently reported that
the FcγRIIIA-158F allele is a risk factor for nephritis in
white patients with SLE. The exact role of these ‘low-affin-
ity’ polymorphisms in disease susceptibility and expres-
sion remains controversial and further work is needed to
fully elucidate their role.
These studies suggest that certain genetic defects (e.g. in
complement, mannose-binding protein, and FcγR) associ-
ated with similar pathogenic mechanisms all can lead to
susceptibility to SLE in different populations. The clinical
expression of SLE, while diverse, may not be nearly as
diverse as the range of genetic defects that may predis-
pose to it. In addition, some genes not associated with
susceptibility may nevertheless be important in phenotypic
expression (e.g. those for IL-6, IL-10). In view of these
observations, enriching populations with a particular
Arthritis Research    Vol 3 No 6 Ahmad and Bruce
Table 3
Human systemic lupus erythematosus susceptibility loci identified in two or more mapping studies
Moser et al  Gaffney et al  Gaffney et al  Shai et al  Lindqvist et al 
Locus (1998) [15] (1998) [16] (2000) [17] (1999) [18] (2000) [19]
1p36 D1S234 D1S468 D1S468
1q23 FcγRIIA D1S484
1q41–44 D1S3462 D1S235 D1S2785
2q32–37 D2S1391 D2S126 D2S125
3q11 D3S2406 D3S1271
4p15 D4S403 D4S403
4q28–31 D4S2431 D4S424 D4S413*
6p11–22 D6S426* D6S276
14q11–23 D14S276 D14S258
16q12–13 D16S415 D16S3136
20p12–13 D20S186 D20S115
20q11–13 D20S481 D20S3119 D20S195
Information taken from from references [15–19]. *Based on a combined analysis of [16,17].phenotype might influence studies of susceptibility.
Prospective studies will be important, both to accurately
assess the association of certain markers with expression
of disease and also to study the predictive value of
genetic markers in defined populations.
Conclusion
The past decade has witnessed major advances in our
understanding of the immunopathogenesis of SLE. Inten-
sive study of several mouse models has allowed signifi-
cant progress towards understanding the genetic
contribution to the development and expression of the
disease. The observed genetic synteny between human
and murine loci provides valuable clues to the origins of
human SLE, and future studies will make possible a
clearer understanding of the role of genetic factors in
disease susceptibility. The next challenge will be to focus
on genetic and molecular pathways that determine an indi-
vidual’s particular phenotype as an aid to prognostication
and early intervention to prevent complications.
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